Given the dismal prognosis for GBM patients, these conceptual findings motivate consideration of clinical trials aimed to evaluate TCAs such as imipramine combined with VEGF/VEGFR pathway inhibitors and immune-checkpoint blockade. The gene discussed is KDR; the disease is glioblastoma.